Full-Time

Vice President, Head of Commercial Operations

Remix Therapeutics

Remix Therapeutics

11-50 employees

Biotech firm developing mRNA-degrading therapies

Compensation Overview

$293k - $358k/yr

+ Bonus + Equity Grants

Belmont, MA, USA

In Person

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
Market Research
Forecasting
Data Governance
Data Analysis

Get referred to Remix Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor's degree required; advanced degree in business, science, public health, analytics or a related discipline preferred.
  • Experience in rare disease, precision oncology, rare solid tumors, hematologic malignancies or another specialty market with concentrated customers and complex patient journeys.
  • 15+ years of progressive biopharmaceutical or biotechnology experience, including substantial leadership responsibility across Commercial Operations, Business Insights, Analytics or related commercialization functions.
  • Direct experience supporting at least one U.S. product from late-stage development through launch and early commercialization, with meaningful accountability for launch readiness and commercial infrastructure.
  • Broad, hands-on expertise across forecasting, market research, competitive intelligence, commercial data and analytics, CRM, field operations, incentive compensation and performance reporting.
  • Demonstrated ability to build or materially scale commercial capabilities in a small or mid-sized biotechnology company operating with limited resources and changing timelines.
  • Strong patient-based forecasting and scenario-planning skills, with the ability to connect clinical, regulatory, epidemiologic, access and competitive assumptions to enterprise decisions.
  • Experience selecting and managing commercial data, research, analytics, technology and operations vendors, including budget and performance accountability.
  • Working knowledge of U.S. healthcare delivery, specialty-product data flows and the legal, compliance, privacy and security requirements governing commercial operations.
  • Executive presence and communication skills sufficient to influence cross-functional leaders, external partners, the executive team and Board of Directors.
  • A builder's mindset, strong attention to detail and comfort moving between strategy, analysis and hands-on execution in a fast-changing environment.
Responsibilities
  • Set and lead the enterprise commercial insights agenda, integrating primary and secondary market research, epidemiology, patient journey and treatment-flow analysis, market sizing, customer insights and competitive intelligence.
  • Build, maintain and communicate patient-based forecasts for ACC and future indications; partner with Finance on revenue scenarios, long-range planning and sensitivity analyses.
  • Translate clinical and regulatory outcomes, target product profile assumptions, biomarker prevalence, treatment patterns, market access dynamics and competitive developments into clear commercial implications.
  • Develop a sequenced learning plan that addresses the highest-value uncertainties for indication prioritization, positioning, go-to-market design, field planning, access strategy and lifecycle management.
  • Create compliant mechanisms to capture and synthesize insights from customers, field teams, patient services, payers, external experts and data sources, then convert those insights into decisions and action.
  • Support portfolio strategy, business development and new-product planning through commercial opportunity assessments, analog analyses and scenario modeling.
  • Develop a phase-appropriate commercial data and analytics roadmap that supports pre-launch decisions, launch execution and post-launch performance management.
  • Select, integrate and govern data from market research, claims, specialty pharmacy and distribution, patient services, market access, CRM, finance and other sources to create a reliable commercial source of truth.
  • Design and implement the commercial technology stack, including CRM, business intelligence and dashboarding, data integration, customer master data, affiliations and account hierarchies.
  • Establish data governance, quality standards, access controls, privacy and compliance requirements, vendor service levels and documentation in partnership with IT, Legal and Compliance.
  • Build decision-oriented dashboards and reporting for executive leadership and commercial teams, balancing leading indicators, launch-readiness metrics and business outcomes.
  • Manage commercial data, analytics and technology partners, ensuring fit-for-purpose solutions, disciplined budgets, strong performance and scalable architecture.
  • Lead field force sizing, structure, territory design, targeting, customer segmentation, call planning and workload analyses for a focused rare-oncology model.
  • Build the field operations model, including CRM processes, activity standards, reporting, field communications, operational support and performance-management routines.
  • Design incentive compensation strategy, measures, governance and administration in partnership with Sales, Human Resources, Finance, Legal and Compliance.
  • Establish field performance dashboards and analytical approaches that distinguish activity, execution quality, customer response, access progression and business impact.
  • Establish the commercial operating cadence, planning processes, governance forums, standard work and decision-support tools required for a lean and accountable organization.
  • Coordinate commercial budget planning and tracking with the Chief Commercial Officer and Finance; provide clear visibility into commitments, forecast changes, investment choices and return expectations.
  • Partner with Market Access and Finance to incorporate pricing, access, channel, patient services and gross-to-net assumptions into forecasts and performance reporting.
  • Build and govern the external commercial partner ecosystem, including scopes of work, selection, contracting support, performance metrics, issue resolution and knowledge transfer.
  • Develop scalable business processes and controls that support commercialization, public-company readiness and compliant operations without creating unnecessary infrastructure.
  • Build and lead a lean, high-performing Commercial Operations and Business Insights organization, sequencing internal hires and external partners against development and launch milestones.
  • Serve as Remix's senior internal authority on commercial analytics, operating model, field effectiveness, performance management and launch execution.
  • Represent Commercial Operations and Business Insights on program teams, launch governance and executive forums; communicate complex analyses and trade-offs with clarity and drive timely decisions.
  • Maintain effective and compliant working boundaries across Commercial and Medical Affairs while ensuring insights are shared appropriately and enterprise decisions remain coordinated.
  • Foster a culture of accountability, collaboration, scientific integrity, urgency and patient focus consistent with Remix's values and team behaviors.
Desired Qualifications
  • Experience launching an oral oncology or specialty-pharmacy product and working with specialty pharmacy, distribution, patient services, claims and access data.
  • Familiarity with ACC, AML, MDS or biomarker-defined oncology populations and the dynamics of academic centers, community oncology and health systems.
  • Prior experience as an early commercial leader preparing a biotechnology company for its first launch.
  • Experience building a commercial data architecture and CRM environment from a blank sheet or materially redesigning an existing model.
  • Experience operating in a public or public-company-ready environment and presenting forecasts, launch readiness or performance recommendations to a Board.

Remix Therapeutics develops medicines for rare diseases with a focus on targeted mRNA degradation. Its lead product REM 422 is an oral small molecule that degrades messenger RNA to stop production of disease-causing proteins. REM 422 is in Phase 1 trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, with FDA Orphan Drug Designation to support development. Remix funds its R&D through grants and partnerships, aiming to bring safe, effective therapies to patients and expand its portfolio.

Company Size

11-50

Company Stage

Growth Equity (Venture Capital)

Total Funding

$224.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Get referred to Remix Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 24, 2026 financing raised $100 million, funding operations into 2028.
  • SEC filing on August 6, 2026 confirms closing path and 2028 runway.
  • 2027 registrational ACC data and AML/HR-MDS readouts create multiple catalysts.

What critics are saying

  • December 24, 2026 is the outside date; failure kills the Passage merger.
  • REM-422 dominates value; any weak 2027 ACC or AML data crushes valuation.
  • Passage holders receive only 7% ownership, signaling leverage and integration fragility.

What makes Remix Therapeutics unique

  • REM-422 targets MYB, a historically undruggable cancer driver, with oral dosing.
  • June 24, 2026 merger preserves Remix’s RNA-processing platform and Nasdaq access.
  • Remaster platform reprograms RNA processing, creating multiple shots on goal beyond REM-422.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

0%

2 year growth

4%
Pharma Journalist
Jun 25th, 2026
Remix Therapeutics to merge with Passage Bio.

Remix Therapeutics to merge with Passage Bio. On Jun 25, 2026 Remix Therapeutics and Passage Bio have agreed to merge in an all-stock transaction, creating a combined biotechnology company focused on advancing RNA-targeted therapies for cancer and other serious diseases. The deal is backed by a new $100 million private financing, providing the merged company with the resources needed to advance its clinical pipeline through several key development milestones. Following the completion of the transaction, the combined company will operate under the name Remix Therapeutics, Inc. and is expected to trade on the Nasdaq stock exchange under the ticker symbol "RMTX." Alongside the merger announcement, Remix revealed that it has secured commitments for an oversubscribed private placement financing led by Decheng Capital, with participation from Lynx1 Capital Management, Forge Life Science Partners, existing investors, and several other institutional investment firms. The financing is expected to close immediately before the merger is finalized. The combined company expects its cash position, including proceeds from the private placement, to fund operations into 2028. The funding is intended to support several important clinical milestones, including data from the registrational Phase 2 trial of REM-422 in Adenoid Cystic Carcinoma (ACC), results from a Phase 1 trial evaluating the therapy in Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS), as well as continued investment in Remix's discovery pipeline. The merger strengthens Remix's position as it develops a new class of small-molecule medicines designed to modulate RNA processing. Unlike conventional therapies that target proteins directly, Remix's platform focuses on controlling how RNA is processed inside cells, offering the potential to treat diseases driven by genetic abnormalities that have historically been difficult to target with existing drugs. At the center of the company's pipeline is REM-422, an orally administered mRNA degrader that targets MYB, a transcription factor involved in several cancers. MYB has long been considered one of the most challenging cancer targets for drug developers, making REM-422 a potentially significant advance if ongoing clinical studies continue to produce positive results. Peter Smith, Ph.D., co-founder and Chief Executive Officer of Remix Therapeutics, described the merger as a transformative milestone for the company. He said the transaction provides the financial strength and operational support needed to accelerate the development of RNA-targeted medicines while expanding the company's proprietary platform. Smith added that the financing and merger position Remix to rapidly advance REM-422 and other pipeline candidates, with the goal of delivering innovative treatment options for patients with cancers that currently have limited therapeutic choices. For Passage Bio, the agreement follows an extensive review of strategic alternatives aimed at maximizing shareholder value. President and Chief Executive Officer Dr. Will Chou said Remix emerged as the ideal partner because of its differentiated RNA processing technology and encouraging early clinical data for REM-422 in adenoid cystic carcinoma. Chou noted that the ongoing registrational study, combined with the company's experienced leadership team, offers Passage Bio shareholders the opportunity to participate in a clinical-stage biotechnology company with a clearly defined path toward pivotal clinical data. The merger reflects growing investor confidence in RNA-based drug development, an area that has attracted increasing attention across the biotechnology industry. By combining Passage Bio's public company infrastructure with Remix's clinical-stage pipeline and fresh capital, the new organization aims to accelerate the development of innovative RNA-targeted therapies and expand treatment options for patients with difficult-to-treat cancers.

BioSpace
Jun 25th, 2026
Passage Bio and Remix Therapeutics Announce Merger Agreement

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Boston Cambridge Biotech Networks
Jun 25th, 2026
Remix Therapeutics secures $100M and a reverse merger.

Remix Therapeutics secures $100M and a reverse merger. June 25, 2026 BCBN news, syndication comments off on remix therapeutics secures $100M and a reverse merger. The deal with Passage Bio includes commitments for $100 million in private placement financing led by Decheng Capital. Click here to view original post

MarketScreener
Jun 24th, 2026
Passage Bio and Remix Therapeutics merge in $100M deal to advance RNA cancer therapies

Passage Bio and Remix Therapeutics have announced a definitive merger agreement, with the combined company to operate as Remix Therapeutics and trade on Nasdaq under ticker symbol "RMTX". Upon closing, pre-merger Passage Bio shareholders will own approximately 7% of the combined entity, whilst Remix stockholders will hold 93%. Concurrent with the merger, Remix has secured an oversubscribed $100 million private placement financing led by Decheng Capital. The funding is expected to support operations into 2028 and deliver several clinical readouts for Remix's lead programme, REM-422, an orally available mRNA degrader targeting MYB, in 2027. The transaction, unanimously approved by both boards, is expected to close in the fourth quarter of 2026, subject to shareholder approval and customary closing conditions. The combined company will be led by Remix CEO Peter Smith.

The Manila Times
Nov 3rd, 2025
Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference

Remix Therapeutics to present at Guggenheim Second Annual Healthcare Innovation Conference. WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10, 2025 at 2:15 PM ET The Remix management team will also be hosting one-on-one meetings with investors. For those investors interested in scheduling a meeting, please contact your Guggenheim representative. About Remix Therapeutics Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). For more information visit www.remixtx.com.